Profile data is unavailable for this security.
About the company
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.
- Revenue in GBP (TTM)128.80m
- Net income in GBP-43.19m
- Incorporated1996
- Employees861.00
- LocationOXBWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
- Phone+44 186 578 3000
- Fax+44 186 578 3001
- Websitehttps://www.oxb.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scancell Holdings Plc | 0.00 | -15.81m | 106.27m | 61.00 | -- | -- | -- | -- | -0.0171 | -0.0171 | 0.00 | -0.015 | 0.00 | -- | -- | 0.00 | -81.40 | -31.66 | -625.06 | -37.66 | -- | -- | -- | -822.37 | -- | -42.23 | 251.00 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
Avacta Group Plc | 11.26m | -29.43m | 123.80m | 151.00 | -- | 12.74 | -- | 10.99 | -0.085 | -0.1496 | 0.0327 | 0.0251 | 0.1854 | 0.00 | 2.64 | 74,576.16 | -48.46 | -43.48 | -172.33 | -78.27 | 44.59 | 63.54 | -261.32 | -781.44 | 1.08 | -0.5712 | 0.7229 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
Bioventix PLC | 13.66m | 7.85m | 144.99m | 17.00 | 18.74 | 12.84 | 18.23 | 10.61 | 1.48 | 1.48 | 2.58 | 2.16 | 1.04 | 2.17 | 2.21 | 803,738.30 | 59.98 | 58.33 | 69.06 | 63.62 | 90.95 | 93.09 | 57.42 | 64.12 | 6.69 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
4Basebio PLC | 933.00k | -12.33m | 155.09m | -- | -- | 5.87 | -- | 166.23 | -0.9391 | -0.9391 | 0.0711 | 1.70 | 0.0329 | 0.8584 | 4.78 | -- | -43.54 | -36.81 | -48.26 | -40.98 | 67.52 | 69.88 | -1,321.87 | -1,160.83 | 11.18 | -19.68 | 0.3658 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
Faron Pharmaceuticals Oy | 0.00 | -22.44m | 233.36m | 25.00 | -- | -- | -- | -- | -0.2682 | -0.2682 | 0.00 | -0.0808 | 0.00 | -- | -- | 0.00 | -227.96 | -227.46 | -- | -1,738.54 | -- | -- | -- | -- | -- | -2.58 | 5.15 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
Puretech Health PLC | 3.58m | 39.64m | 315.10m | 56.00 | 7.42 | 1.02 | 13.57 | 88.10 | 0.1764 | 0.1764 | 0.014 | 1.28 | 0.0075 | -- | 2.48 | 63,867.54 | 4.29 | -3.27 | 4.57 | -3.83 | -- | -- | 575.43 | -253.25 | -- | -- | 0.052 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
Oxford BioMedica plc | 128.80m | -43.19m | 373.60m | 861.00 | -- | 6.54 | -- | 2.90 | -0.414 | -0.414 | 1.24 | 0.5384 | 0.5322 | 5.73 | 4.71 | 149,590.00 | -20.09 | -20.23 | -25.99 | -25.48 | 41.17 | 49.36 | -37.74 | -45.03 | 2.05 | -5.42 | 0.6426 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
Allergy Therapeutics plc | 55.66m | -35.65m | 393.23m | 602.00 | -- | -- | -- | 7.07 | -0.0075 | -0.0075 | 0.0117 | -0.0015 | 0.7836 | 2.15 | 6.00 | 92,453.49 | -50.19 | -22.88 | -78.92 | -30.15 | 54.04 | 66.47 | -64.05 | -24.88 | 1.15 | -4.07 | 1.19 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
Genus plc | 671.60m | -4.00m | 1.47bn | 3.44k | -- | 2.84 | 37.21 | 2.18 | -0.0612 | -0.0612 | 10.16 | 7.82 | 0.6585 | -- | 6.11 | 195,289.30 | -0.6275 | 3.30 | -0.7199 | 3.87 | -- | -- | -0.953 | 4.98 | 1.33 | -- | 0.3656 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
Holder | Shares | % Held |
---|---|---|
Briarwood Chase Management LLCas of 09 Jun 2025 | 13.85m | 13.07% |
Vulpes Investment Management Pte Ltd.as of 21 Mar 2025 | 8.45m | 7.97% |
M&G Investment Management Ltd.as of 21 Mar 2025 | 5.87m | 5.54% |
Liontrust Investment Partners LLPas of 29 Oct 2024 | 5.27m | 4.97% |
Threadneedle Asset Management Ltd.as of 21 Mar 2025 | 3.83m | 3.62% |
Barclays Bank Plc (Private Banking)as of 01 Jun 2025 | 3.78m | 3.57% |
BlackRock Investment Management (UK) Ltd.as of 01 Oct 2024 | 3.64m | 3.44% |
Hargreaves Lansdown Asset Management Ltd.as of 21 Mar 2025 | 3.48m | 3.28% |
Charles Schwab Investment Management, Inc.as of 01 Jun 2025 | 2.73m | 2.58% |
Banque Pictet & Cie SAas of 01 Jun 2025 | 2.07m | 1.96% |